2morrow is a leader in digital behavioral health, providing evidence-based health and wellness programs to some of the nation's largest employers, states, and health plans. Founded in 2011 by a nurse and a medical device engineer, 2morrow's vision is to increase access to care by combining behavioral science and smartphone technology. 2morrow has helped over half a million people improve their lives using our digital health programs. At 2morrow, evidence is part of our DNA. With over 20 studies and one of the few Phase III clinical trials in digital health, 2morrow continues to be at the forefront of the emerging digital health and digital therapeutic industry.

2Strands is an innovative early-stage precision diagnostic company developing blood-based monitoring tests for cancer patients. Our vision is to revolutionize oncology practice with a solution that delivers a unique combination of accuracy, affordability, and speed. 2Strands' innovative assay chemistry uses proprietary biochemical steps and next-gen computational modeling to achieve exceptional performance.

4basecare, an Illumina-backed company headquartered in Singapore, is engaged in developing cutting-edge precision oncology solutions using advanced genomics and next-gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enable oncologists to choose the optimal precision therapies for their patients. Our coveted genomic testing portfolio assesses the tumor genomic alterations by NGS from tissue or liquid biopsy for somatic mutation analysis and germline mutation testing for hereditary and familial cancer from peripheral blood to personalize patient care in oncology. 4basecare is backed by a highly experienced advisory board who are leaders in genomics and technology. Among them is Lip Bu Tan, chairman of Walden International and advisor to Yali Capital, which has invested in 4basecare. Also on the board is Francis Desouza, a Silicon Valley tech veteran and former CEO of Illumina, who brings over 30 years of expertise in genomics, technology, and healthcare. 4basecare’s journey has been marked by significant milestones in both funding and growth. The company has raised $6 million in Series A funding led by Yali Capital with participation from Mathew Cyriac. In March 2021, 4basecare had raised $2 million led by Mount Judi Ventures, GrowX Ventures, Season Two Ventures, First In Ventures, and other angel investors. 4basecare’s test has made a significant impact in Southeast Asia, with over 10,000 cancer patients taking the test. 4basecare has collaborations with more than 300 oncologists in India. This growing network with oncologists and leading hospitals in India ensures that more patients are able to opt for personalized cancer care.

Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a hydrophilic material which retains significant amounts of water. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade the foreign body response and complications that come with it. Our cleared products are Hydropicc® and Hydromid®. For more information, please visit www.accessvascularinc.com.

Aevice Health Pte Ltd is a Singapore-based medtech spin-off from Nanyang Technological University at the forefront of addressing chronic respiratory disease, one of the generation’s biggest healthcare challenges. The company’s non-invasive wearable devices enable the early detection of cardiopulmonary abnormalities remotely and in real-time, so that patients can receive fast and targeted care from the ease of their homes. Clinicians can also gain insights into their patients’ health and track their responses to treatment plans easily from the Aevice analytical platform. In Aevice Health, our mission is to drive medical innovations that transform healthcare, improve outcomes and empower lives. More information about the company can be found at www.aevice.com.

Aksense is developing a quick blood test to help people who are suffering from healthcare-associated infections, with testing for these infections in one minute using a portable electronic biosensor, without a lab or expert, saving lives, time, and money. Contact us to find out more.

A Techstars-backed company, Alva Health’s mission is to help older Americans living with high stroke risk to prevent disability, live independently, and to bring peace of mind to their families.

Anumana™ is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with life-saving treatments. Anumana recently acquired Neutrace and is leveraging the power of novel ECG-EGM-EMR integration for clinically valuable, actionable insights. With Nference’s proprietary NSIGHTS real-world evidence generation platform, built on data from leading health systems, we combine unparalleled longitudinal structured and unstructured electronic medical record data with diagnostic and interventional ECGs and EGMs. By applying AI techniques to these electrical signals from the heart, the company has uncovered clinically critical electrical signatures and patterns unrecognizable to the human eye. The resulting software products can be integrated into routine clinical practice for earlier disease diagnosis and in-procedure decision-making. Anumana’s 75+ peer-reviewed publications and ongoing research show significant promise to detect and diagnose otherwise hidden conditions earlier and uncover actionable insights for valuable patient interventions. The opportunity to offer clinical decision support tools for each unique patient throughout the cardiac care continuum paves the way for precision medicine. Anumana strives to introduce a new standard of care in cardiac clinical care supported by reimbursement.

We are revolutionizing bio-nanoparticle purification and exosome-based therapeutics.

Astek is a precision diagnostics company, advancing the JIDDU system for confirming bacterial infections and assessing antibiotic sensitivity in various sample types: urine, CSF, effluent, and blood. This groundbreaking technology aims to enhance diagnostic speed and accuracy, reduce patient complications, and lower healthcare costs. Our initial focus is launching a urine-based test in 2025 that swiftly identifies UTI infections and determines antibiotic sensitivity within an hour.

Atom Bioworks has developed a platform for programming biomolecules as high-affinity binders for therapeutics.